Animal and early-stage human trial data for Amgen’s experimental obesity drug published in a medical journal showed that it promoted significant weight loss with an acceptable safety profile, the company said on Monday.
https://www.pharmalive.com/wp-content/uploads/2020/10/Osteoporosis-drug-helps-Amgen-third-quarter-profit-beat-estimates-Reuters-10-28-20.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2024-02-05 05:30:262024-02-05 09:44:11Promising early data details on Amgen weight-loss drug published
